Cathay Biotech released its semi-annual report for 2025, achieving operating revenue of 1.671 billion yuan in the first half of the year, a year-on-year increase of 15.68%; net profit attributable to the parent company was 309 million yuan, a year-on-year increase of 24.74%. During the reporting period, the company's series of long-chain dicarboxylic acids continued to ramp up production, with sales revenue and gross profit from sales continuously rising, driving growth in operating revenue, total profit, and net profit compared to the same period last year